跳至主要内容
临床试验/NCT00568737
NCT00568737已完成3 期

Efficacy and Safety of Drotrecogin Alfa (Activated) in Adult Patients With Early Stage Severe Sepsis

Eli Lilly and Company1 个研究点 分布在 1 个国家目标入组 2,640 人开始时间: 2002年11月最近更新:
适应症
干预措施
相关药物

试验速览

阶段
3 期
状态
已完成
入组人数
2,640
试验地点
1
主要终点
Efficacy

研究概览

简要总结

Adult Patients with Severe Sepsis

详细描述

Compared with placebo, drotrecogin alfa (activated) reduces 28-day all-cause mortality in adult patients with severe sepsis at low risk of death (for example, with an Acute Physiology and Chronic Health Evaluation II (APACHE II) score <25 or single organ dysfunction).

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Treatment
盲法
Double (Participant, Investigator)

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Adult patients with recent onset of severe sepsis or presence of a suspected or proven infection, and at least one induced organ dysfunction.

排除标准

  • Are indicated for the treatment with drotrecogin alfa (activated) under the applicable label in the investigative site country.
  • Are contraindicated for treatment with drotrecogin alfa (activated) under the applicable label in the investigative site country.
  • Platelet count less than 30,000/mm3.

研究组 & 干预措施

1

Experimental

24 microgram/kg/hr for 96 hours (+ or - 1 hour)

干预措施: Drotrecogin alfa (activated) (Drug)

2

Placebo Comparator

0.9% sodium chloride

干预措施: Placebo (Drug)

结局指标

主要结局

Efficacy

时间窗: 20 months

次要结局

  • Safety(20 months)

研究者

申办方类型
Industry

研究点 (1)

Loading locations...

相似试验